Literature DB >> 27646909

Fifty-Five Years of Pediatric Endocrinology and 50 Years of the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases in Slovenia.

Tadej Battelino1.   

Abstract

Paediatric endocrinology started its independent development early in the general development of this specialty, with a strong focus on research and clinical excellence. Slovenian paediatric endocrinology was an integral part of the European paediatric endocrinology from its beginnings and a founding member of the first 'International Study Group for Diabetes in Children and Adolescents'. After the pioneering work of Prof. Lev Matajc, Prof. Ciril Kržišnik firmly integrated the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases at the University Children's Hospital in Ljubljana in the international scientific community. In the last decade, the department participates in cutting-edge research and provides clinical services at highest international standards.

Entities:  

Keywords:  Slovenia; clinical care; diabetes; metabolic diseases; paediatric endocrinology; research

Year:  2015        PMID: 27646909      PMCID: PMC4820168          DOI: 10.1515/sjph-2015-0009

Source DB:  PubMed          Journal:  Zdr Varst        ISSN: 0351-0026


The field of clinical endocrinology developed parallel to the development of biochemistry, with identification of chemical substances called hormones. Descriptions of first successful treatments of diseases related to hormones appeared at the beginning of the 20th century and, in 1917 ‘The Association for the Study of Internal Secretions’ (now ‘The Endocrine Society’) was established in the United States, along with its journal ‘Endocrinology’ (now ‘The Journal of Clinical Endocrinology and Metabolism’). In Europe, ‘The Society for Endocrinology’ was established in the United Kingdom in 1946, followed by other countries like Germany, in 1964, with ‘Deutsche Gesellschaft für Endokrinologie’. The development of paediatric endocrinology was based on a very strong and active research in this field and, in 1962, the ‘European Society for Paediatric Endocrinology’ (ESPE) was established, preceding any similar internal medicine association in the old continent. In the United States, a very active group of paediatric endocrinologists from Johns Hopkins University formalized in 1964, and transformed into a national association called the ‘Lawson Wilkins Pediatric Endocrine Society’ in 1972 (now ‘The Pediatric Endocrine Society’). In Slovenia, paediatric endocrinology started with the activities of Prof. Lev Matajc. The first children with endocrine diseases were treated at the University Children Hospital in Ljubljana in the late fifties. Prof. Matajc formally established the Section of paediatric endocrinology in 1963 (1, 2), and after visiting Prof. Henry Lestradet in Paris, he introduced self-control for children with diabetes, started with diabetes summer camps in 1967 (they are organized annually since), national childhood diabetes registry in 1970, and a bulletin for young patients and their families in 1971. In 1974, Prof. Matajc was among the founding members of the paediatric diabetes society ‘International Study Group for Diabetes’ (in childhood and adolescence) (ISGD), established in Paris under the initiative of Prof. Lestradet (and transformed in 1993 into the ‘International Society for Pediatric and Adolescent Diabetes’ (ISPAD)). Additionally, in 1969, Prof. Matajc was among the first in Europe using human growth hormone extracted from cadaveric pituitaries for treating growth hormone deficiency. The leadership in Slovenian paediatric endocrinology was forwarded to Prof. Ciril Kržišnik, who took over the Section of pediatric endocrinology, diabetes and metabolic diseases in 1982, and upgraded it to the Department of the University Children’s Hospital in 1990. His main legacy was integrating the department and its research activities into the international collaboration (EURODIAB, DIAMOND) and professional societies. By organizing the 15th ISPAD annual congress in 1989 in Slovenia, he settled the department on the map of international centres. He continued with this initiative, and participating in the writing of the first WHO-IDF-ISPAD guidelines, was a founding member of the ‘Alpe-Adria Study Group for Paediatric Endocrinology and Diabetes’ (AASGPED) in 1990, the ‘Middle European Working-group of Paediatric Endocrinology’ (MEWPE) in 1994, and the ‘Mediterranean Society for Paediatric Endocrinology’ (MSPE) in 1995. Increasing research activities and international collaboration of the department enabled him to bring the 42nd annual congress of the ‘European Society for Paediatric Endocrinology’ to Ljubljana in 2003. In addition to his professional endeavour, he became the medical director of the University Children’s Hospital (UCH) in 1996, and conducted the construction of a new, modern building into which the UCH moved in 2009, providing the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases with the environment and means for further clinical excellence and research. In the last decade, the Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases at the UCH in Ljubljana, shoulders a central role in conducting cutting-edge research in the field of diabetes (3), endocrinology (4–6) and metabolic diseases (7, 8), and maintains internationally comparable excellence in providing medical care (9, 10). The department has a strong vision to further increase integration into European research structures (it currently participates in two ESPE research grants, in two EU grants, and has three grants from the Slovene National Research Agency), quality assurance programs (it obtained the SWEET-IDF-ISPAD certificate in 2014) and clinical excellence. Finally, tight cooperation with the Laboratory for Medical Genetics at the UCH Ljubljana also fosters applied basic research (11–19). The current issue of the Slovenian Journal of Public Health (Zdravstveno varstvo) kindly hosts the department’s anniversary by publishing articles based on recent research and clinical activities. Our own results were combined with results from a lively international collaboration into an assortment of original data and information. All these aims and endeavours are driven by the needs of our chronically ill children, adolescents, young adults and their families – our success will be measured by how much we alleviate day-to-day burden of their diseases.
  17 in total

1.  Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring--implications for clinical management of patients with hyperphenylalaninemia.

Authors:  Urh Groselj; Simona Murko; Mojca Zerjav Tansek; Jernej Kovac; Alenka Trampus Bakija; Barbka Repic Lampret; Tadej Battelino
Journal:  Clin Biochem       Date:  2014-09-28       Impact factor: 3.281

2.  Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.

Authors:  Jean de Schepper; Michael Højby Rasmussen; Zoran Gucev; Alon Eliakim; Tadej Battelino
Journal:  Eur J Endocrinol       Date:  2011-07-01       Impact factor: 6.664

3.  Newborn screening in southeastern Europe.

Authors:  Urh Groselj; Mojca Zerjav Tansek; Andraz Smon; Natalija Angelkova; Dana Anton; Ivo Baric; Maja Djordjevic; Lindita Grimci; Maria Ivanova; Adil Kadam; Vjosa Mulliqi Kotori; Hajrija Maksic; Oana Marginean; Otilia Margineanu; Olivera Milijanovic; Florentina Moldovanu; Mariana Muresan; Simona Murko; Michaela Nanu; Barbka Repic Lampret; Mira Samardzic; Vladimir Sarnavka; Aleksei Savov; Maja Stojiljkovic; Biljana Suzic; Radka Tincheva; Husref Tahirovic; Alma Toromanovic; Natalia Usurelu; Tadej Battelino
Journal:  Mol Genet Metab       Date:  2014-08-01       Impact factor: 4.797

4.  Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED.

Authors:  D Cihakova; K Trebusak; M Heino; V Fadeyev; A Tiulpakov; T Battelino; A Tar; Z Halász; P Blümel; S Tawfik; K Krohn; J Lebl; P Peterson
Journal:  Hum Mutat       Date:  2001-09       Impact factor: 4.878

5.  Five novel mutations and two large deletions in a population analysis of the phenylalanine hydroxylase gene.

Authors:  Urh Groselj; Mojca Zerjav Tansek; Jernej Kovac; Tinka Hovnik; Katarina Trebusak Podkrajsek; Tadej Battelino
Journal:  Mol Genet Metab       Date:  2012-04-01       Impact factor: 4.797

6.  Genetic risk for co-occurrence of type 1 diabetes and celiac disease is modified by HLA-C and killer immunoglobulin-like receptors.

Authors:  D Smigoc Schweiger; A Mendez; S Kunilo Jamnik; N Bratanic; N Bratina; T Battelino; J Brecelj; B Vidan-Jeras
Journal:  Tissue Antigens       Date:  2014-11

7.  Severe progressive obstructive cardiomyopathy and renal tubular dysfunction in Donohue syndrome with decreased insulin receptor autophosphorylation due to a novel INSR mutation.

Authors:  Tinka Hovnik; Nevenka Bratanič; Katarina Trebušak Podkrajšek; Jernej Kovač; Darja Paro; Tomaž Podnar; Nataša Bratina; Tadej Battelino
Journal:  Eur J Pediatr       Date:  2012-12-11       Impact factor: 3.183

8.  Detection of a complete autoimmune regulator gene deletion and two additional novel mutations in a cohort of patients with atypical phenotypic variants of autoimmune polyglandular syndrome type 1.

Authors:  Katarina Trebusak Podkrajsek; Tatjana Milenković; Roelof J Odink; Hedi L Claasen-van der Grinten; Nina Bratanic; Tinka Hovnik; Tadej Battelino
Journal:  Eur J Endocrinol       Date:  2008-08-05       Impact factor: 6.664

9.  Decreased prevalence of hypercholesterolaemia and stabilisation of obesity trends in 5-year-old children: possible effects of changed public health policies.

Authors:  Katarina Sedej; Primož Kotnik; Magdalena Avbelj Stefanija; Urh Grošelj; Andreja Širca Čampa; Lara Lusa; Tadej Battelino; Nataša Bratina
Journal:  Eur J Endocrinol       Date:  2014-02-01       Impact factor: 6.664

10.  Interleukin-1β downregulates RBP4 secretion in human adipocytes.

Authors:  Primoz Kotnik; Michaela Keuper; Martin Wabitsch; Pamela Fischer-Posovszky
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.